Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Shares Outstanding for 8 consecutive years, with $25.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 347.68% year-over-year to $25.1 million, compared with a TTM value of $25.1 million through Sep 2025, up 347.68%, and an annual FY2024 reading of $5.7 million, up 2.1% over the prior year.
  • Shares Outstanding was $25.1 million for Q3 2025 at X4 Pharmaceuticals, up from $8.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $168.5 million in Q3 2024 and bottomed at $5.6 million in Q4 2023.
  • Average Shares Outstanding over 5 years is $54.4 million, with a median of $25.1 million recorded in 2025.
  • The sharpest move saw Shares Outstanding soared 430.53% in 2023, then plummeted 96.59% in 2024.
  • Year by year, Shares Outstanding stood at $28.1 million in 2021, then surged by 332.55% to $121.7 million in 2022, then plummeted by 95.41% to $5.6 million in 2023, then grew by 2.1% to $5.7 million in 2024, then soared by 341.3% to $25.1 million in 2025.
  • Business Quant data shows Shares Outstanding for XFOR at $25.1 million in Q3 2025, $8.0 million in Q2 2025, and $5.8 million in Q1 2025.